Physician profile
Amy Carter
NPI 1982225884
$11,246.32
in general payments reported to CMS, 2019-2025
55 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $1,925 · 2023: $2,621 · 2024: $3,234 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,546 · Education: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,545.93 |
| Education | $680.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,422.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,373.27 | 2021-2025 | Lynparza, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $885.28 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $834.71 | 2021-2025 | Tukysa, Padcev, Adcetris |
| Pfizer INC. | $651.99 | 2021-2025 | |
| Amgen INC. | $357.40 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $339.55 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Astellas Pharma US INC | $300.78 | 2021-2025 | Xtandi, Padcev, Vyloy |
| Genentech USA, INC. | $299.61 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Incyte Corporation | $299.26 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $272.40 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $258.44 | 2021-2025 | |
| Daiichi Sankyo INC. | $245.92 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $233.97 | 2022-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $230.35 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $216.75 | 2021-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $214.35 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $207.65 | 2021-2024 | Cabometyx |
| Janssen Biotech, INC. | $204.46 | 2023-2025 | Rybrevant, Imbruvica, Erleada |
| Glaxosmithkline, LLC. | $178.51 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $162.57 | 2023-2025 | |
| Sobi, INC | $156.21 | 2023-2025 | |
| Gilead Sciences, INC. | $156.15 | 2022-2025 | Trodelvy |
| Acrotech Biopharma INC. | $140.10 | 2022-2025 | Beleodaq |
| Beigene USA, INC. | $132.19 | 2023-2025 | Brukinsa |
| Epizyme, INC. | $121.36 | 2021 | |
| Adaptive Biotechnologies Corporation | $116.56 | 2022-2025 | Clonoseq |
| Genzyme Corporation | $110.99 | 2022-2024 | |
| Eisai INC. | $99.95 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $73.55 | 2024 | Ultomiris |
| Array Biopharma INC | $72.97 | 2021-2024 | Lorbrena, Braftovi, Mektovi |
| Beone Medicines USA, INC. | $67.97 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $66.99 | 2022-2025 | |
| Tersera Therapeutics LLC | $59.98 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $53.17 | 2024 | Orgovyx |
| Karyopharm Therapeutics INC. | $52.82 | 2021-2024 | Xpovio |
| G1 Therapeutics, INC. | $52.35 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $49.16 | 2021-2024 | Cosela |
| Stemline Therapeutics INC. | $48.50 | 2024-2025 | Orserdu |
| Kite Pharma, INC. | $47.71 | 2023 | |
| Geron Corporation | $46.24 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $45.92 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $44.96 | 2022-2023 | Imbruvica |
| Taiho Oncology, INC. | $35.65 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.84 | 2025 | Onivyde |
| Emd Serono, INC. | $22.43 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.46 | 2024 | Givlaari |
| Adc Therapeutics America, INC. | $18.98 | 2025 | |
| Octapharma USA, INC. | $18.60 | 2023 | Octagam Immune Globulin (Human) |
| Jazz Pharmaceuticals INC. | $18.03 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.98 | 2023 | Opsumit, Uptravi |
| Agios Pharmaceuticals, INC. | $17.90 | 2023 | Pyrukynd |
| Mylan Institutional INC. | $16.84 | 2022 | |
| Servier Pharmaceuticals LLC | $16.26 | 2022 | |
| Deciphera Pharmaceuticals INC. | $13.33 | 2024 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.